Clinical & Administrative Pharmacy Sciences, Howard University College of Pharmacy, Washington, DC, USA.
Department of Pharmacy, Howard University Hospital, Washington, DC, USA.
Expert Rev Hematol. 2024 Jun;17(6):255-260. doi: 10.1080/17474086.2024.2352497. Epub 2024 May 16.
To date, there is limited evidence on patients utilizing both voxelotor and darbepoetin alfa and its impact on hemoglobin levels. The objective is to evaluate the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with SCD.
This was a retrospective chart review study that assessed the primary independent variable as the utilization of either voxelotor alone, darbepoetin alfa alone, or the concurrent administration of voxelotor and darbepoetin alfa. Descriptive statistics were utilized to obtain the mean standard deviation for numerical variables and proportions for categorical variables.
A total of 23 participants were included in this study. When comparing baseline to 2 months and 3 months, participants on voxelotor alone experienced a 3% decrease and a 6.6% increase in hemoglobin, darbepoetin alfa alone group a 4.3% decrease and a 0.6% increase in hemoglobin and voxelotor and darbepoetin group a 4.4% decrease and a 0.5% decrease in hemoglobin levels. Fifty percent of the participants in the voxelotor group and 6 (66.7%) participants in the voxelotor plus darbepoetin alfa group experienced adverse drug events.
Voxelotor resulted in a clinically significant difference in the percent change of hemoglobin from baseline to 3 months.
迄今为止，关于同时使用伏洛托和达贝泊汀α及其对血红蛋白水平影响的患者的证据有限。目的是评估伏洛托对 SCD 患者血红蛋白水平的影响。
这是一项回顾性图表审查研究，将主要的独立变量评估为单独使用伏洛托、单独使用达贝泊汀α或同时使用伏洛托和达贝泊汀α。描述性统计用于获得数值变量的平均值和标准差以及分类变量的比例。
本研究共纳入 23 名参与者。与基线相比，单独使用伏洛托的参与者在 2 个月和 3 个月时血红蛋白分别下降 3%和增加 6.6%，单独使用达贝泊汀α的参与者血红蛋白分别下降 4.3%和增加 0.6%，同时使用伏洛托和达贝泊汀的参与者血红蛋白分别下降 4.4%和下降 0.5%。伏洛托组有 50%的参与者和伏洛托加达贝泊汀α组有 6 名（66.7%）参与者发生药物不良反应。
伏洛托在血红蛋白从基线到 3 个月的百分比变化方面产生了临床显著差异。
